Editors' ChoiceAutoimmunity

PTPN22: A Risky Business

Science Translational Medicine  24 Aug 2011:
Vol. 3, Issue 97, pp. 97ec134
DOI: 10.1126/scitranslmed.3003064

Log in to view full text

Via your Institution

Log in through your institution

Log in through your institution